Financial Performance & Strategy - Brenntag reported Q2 2025 sales of EUR 38694 million, a decrease of 41% compared to the previous year, adjusted for FX[146] - Operating Gross Profit for Q2 2025 was EUR 9743 million, down by 19% year-over-year, FX adjusted[146] - Q2 2025 Operating EBITA reached EUR 2464 million, a 139% decrease compared to the previous year, FX adjusted[146] - The company's cost-out program contributed approximately EUR 30 million in savings during Q2 2025 compared to Q2 2024[145] - Brenntag maintains a capital allocation framework that includes annual Capex of EUR 300-400 million and M&A spending of EUR 400-500 million, implying a ~3% annual Operating EBITA growth contribution[17] Business Divisions - Brenntag Specialties reported FY 2024 Operating Gross Profit of EUR 12 billion and Operating EBITA of EUR 447 million[7] - Brenntag Essentials reported FY 2024 Operating Gross Profit of EUR 29 billion and Operating EBITA of EUR 781 million[7] - Brenntag Essentials aims for a 5-7% CAGR in Operating EBITA by FY27E, driven by portfolio shifts, volume growth, inflation normalization, and operational excellence[74] - Brenntag Specialties targets a 7-9% CAGR in Operating EBITA by FY27E through price and margin management, cost-out initiatives, portfolio management, and value-added services[100] Market Dynamics & Growth - The chemical distribution market is structurally expanding, with a mid-term underlying sales growth of 3-5% per annum[36] - Brenntag aims for a total CAGR of 10-12%, with organic CAGR contributing 7-9% by 2027[20] - M&A remains a core part of Brenntag's growth strategy, with approximately EUR 39 billion spent on over 100 acquisitions since IPO, contributing around 3% annual Operating EBITA growth[6, 14]

Financial Performance - Underlying Revenue from customers reached $256.8 million, a 3.1% year-over-year increase[5] - Recurring Revenue accounted for $154.3 million of the Underlying Revenue[5] - Underlying Cash EBITDA was $43.8 million, resulting in a 17% Cash EBITDA margin[5] - The company ended the year with $58.7 million in cash and no debt[5] - A final FY25 dividend of $13.1 million (2.92c per share) and a special dividend of $8.0 million (1.79c per share) were distributed[5] Segment Performance - EMEA revenue was $186 million in FY25[12] - APAC revenue was $73 million in FY25[12] Future Outlook - The company expects FY26 revenues to be in line with FY25 and Cash EBITDA to be above $50 million[31] - One customer exit will impact FY26 revenue by A$10 million[37] Capital Allocation - A capital return of $73.2 million (16.3 cents per share) was paid in January 2025[28] - A special dividend of $40.0 million (8.92 cents per share) and 1H25 Dividend of $7.2 million (1.6 cents per share) was paid in April 2025[28]

Theravance Biopharma Second Quarter 2025 Financial Results and Business Update August 12, 2025 THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third-party trademarks used herein are the property of their respective owners. © 2025 Theravance Biopharma. All rights reserved. Forward Looking Statements This presentation contains certain "forward-lo ...

Financial Performance - Q2'25 revenue was $156 million, a 17% decrease QoQ and a 5% decrease YoY[15] - GAAP gross loss was $(124) million, while non-GAAP gross loss was $(108) million[16] - Q2'25 GAAP operating expenses were $271 million, and non-GAAP operating expenses were $470 million, including ~$4M in one-time items[16, 11] - Cash and marketable securities stood at $1076 million, excluding undrawn credit facility, equity finance program, and convertible preferred facility[17] - Free Cash Flow (FCF) was $(538) million, compared to $(443) million in Q1'25[19] Debt Management - $50 million of 2026 convertible notes were repurchased via cash & equity[8] - $135 million face amount of 2026 convertible debt remains outstanding as of August 2025, reduced from $625 million in August 2024[8, 13, 14] - The company aims to reduce 2026 convertible debt to below $100 million by year-end 2025[14] Revised Guidance - FY'25 revenue guidance lowered to $67 million to $74 million, based on sensor shipment of 20k to 23K units, down from prior outlook of 30k-33k units[20] - Non-GAAP gross loss is expected to be in the range of $(5) million to $(10) million per quarter through FY'25[20] - Non-GAAP quarterly operating expenses are expected to improve to the low-$30 million range by year-end 2025[20] - The company expects to end FY'25 with $80 million to $100 million in cash and marketable securities[21]

Financial Performance - Revenue for the second quarter of 2025 reached $700.1 million, compared to $689.9 million in the second quarter of 2024[57] - Adjusted EBITDA for the second quarter of 2025 was $82.4 million[58], while the TTM (Trailing Twelve Months) Adjusted EBITDA reached $303.3 million[20] - Net income for the second quarter of 2025 was $38.6 million, compared to $28.5 million in the second quarter of 2024[57] - The company has tightened its FY25 guidance, projecting revenue between $2.75 billion and $2.80 billion, and adjusted EBITDA between $310 million and $320 million[36] Operational Metrics - The number of early childhood education centers increased from 1,568 in June 2024 to 1,589 in June 2025[16] - Before- and after-school sites increased from 944 in June 2024 to 1,043 in June 2025, representing a 4.8% increase[16, 23] - Same-center revenue for early childhood education increased by 1% from $632.3 million to $637.7 million[16, 28] - Average weekly ECE FTEs (Full Time Enrollments) decreased slightly from 151,117 in June 2024 to 149,010 in June 2025[16] Strategic Initiatives and Market Factors - Champions expanded into 5 new districts during Q2, and Champ Camp expanded into 13 new districts, with overall growth of 99 sites in the past 12 months[13] - The new section 45F tax provision increases the annual maximum child care credit for employers from $150,000 to $500,000, and for eligible small businesses, this limit is further increased to $600,000[43] - The company's leverage ratio is 2.7x, with net debt of $807.4 million against a TTM Adjusted EBITDA of $303.3 million[31]

Q2 2025 Earnings Supplemental August 12th, 2025 Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements relate to matters such as our industry, business st ...

SKYH NYSE Investor Presentation Summer 2025 2025 Q2 Earnings Webcast August 12th, 2025 SKYH NYSE ©2025 Sky Harbour Proprietary DISCLAIMER General This presentation and information provided at a webcast or meeting at which it is presented (the "Presentation") is for informational purposes only to assist investors, prospective investors and other parties in making their own evaluation with respect to Sky Harbor Group Corporation ("Sky Harbour"). The information contained herein does not purport to be all-incl ...

Second Quarter 2025 Earnings Presentation August 12, 2025 1 Disclaimer This presentation contains forward-looking statements that can be identified by the use of words such as "anticipate," "believe," "could," "expect," "should," "plan," "intend," "estimate" and "potential," among others. By their nature, forward-looking statements are necessarily subject to a high degree of uncertainty and involve known and unknown risks, uncertainties, assumptions and other factors because they relate to events and depend ...

CoreWeave Q2'25 Earnings Presentation August 12, 2025 1 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of applicable securities laws. Such statements are based on our current expectations, forecasts and assumptions and involve risks and uncertainties. These statements include, but are not limited to, statements related to our business; our strategy; our market opportunity and future growth; market trends; impact of investments in sales and marketing; an ...

Q4 FY25 Conference Call August 12, 2025 Forward Looking Statements and Financial Presentation This presentation and our earnings call contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These include statements regarding: our belief and expectations with respect to our markets, including the cloud end market and the broader networking market, customers and industry, cloud and AI investments and buildout an ...